Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

• Dagmar Kubitza, Michael Becka, Barbara Voith, Michael Zuehlsdorf, Georg Wensing
• Clinical pharmacology and therapeutics
• 2005

BACKGROUND AND OBJECTIVE There is a clinical need for new oral anticoagulants to prevent and treat thromboembolic diseases. Given its integral role in the coagulation cascade, factor Xa is a… (More)

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

• Dagmar Kubitza, Michael Becka, Georg Wensing, Barbara Voith, Michael Zuehlsdorf
• European Journal of Clinical Pharmacology
• 2005

There is a clinical need for safe new oral anticoagulants. The safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY 59-7939—a novel, oral, direct Factor Xa (FXa) inhibitor—were… (More)

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.

• Dagmar Kubitza, Michael Becka, +7 authors Heike Bruck
• British journal of clinical pharmacology
• 2010

AIM This study evaluated the effects of impaired renal function on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban (10mg single dose), an oral, direct Factor Xa inhibitor. METHODS… (More)

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.

• Heino Stass, Axel A H Dalhoff, Dagmar Kubitza, U Schühly
• Antimicrobial agents and chemotherapy
• 1998

The pharmacokinetics of moxifloxacin were investigated in six studies after oral administration of 50, 100, 200, 400, 600, and 800 mg. Eight healthy male volunteers were included in each study. With… (More)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

• Wolfgang Mueck, Jan Stampfuss, Dagmar Kubitza, Michael Becka
• Clinical pharmacokinetics
• 2014

Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma concentrations… (More)

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.

• Wolfgang Mueck, Dagmar Kubitza, Michael Becka
• British journal of clinical pharmacology
• 2013

AIMS The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve cytochrome P450 3A4 (CYP3A4) and 2J2… (More)

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.

• Heino Stass, Dagmar Kubitza
• The Journal of antimicrobial chemotherapy
• 1999

The pharmacokinetics of moxifloxacin and its metabolites M1 (sulpho-compound) and M2 (acyl-glucuronide) were characterized in 12 healthy male volunteers in an open, randomized, crossover study. After… (More)

Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.

• Corinna Weinz, Thomas Schwarz, Dagmar Kubitza, Wolfgang Mueck, Dieter Lang
• Drug metabolism and disposition: the biological…
• 2009

Rivaroxaban is a novel, oral, direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. The objective of this study was to investigate the in vivo metabolism and… (More)

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.

• Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Michael Zuehlsdorf
• Journal of clinical pharmacology
• 2006

Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders. This was a randomized, 2-way crossover… (More)

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.

• Wolfgang Mueck, Michael Becka, Dagmar Kubitza, Barbara Voith, Michael Zuehlsdorf
• International journal of clinical pharmacology…
• 2007

OBJECTIVE Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa (FXa) inhibitor being developed for the prevention and treatment of thromboembolic disorders. This analysis aimed to define population… (More)

• ‹
• 1
• 2
• 3
• 4
• 5
• ›